Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 9/2022

28-05-2022 | Literatur kommentiert

Krebsprädispositions-Screening-Tools zur Vorhersage späterer maligner Erkrankungen bei Überlebenden nach einer Tumorerkrankung im Kindesalter

Author: PD Dr. med. Monika Sparber-Sauer

Published in: Strahlentherapie und Onkologie | Issue 9/2022

Login to get access

Auszug

Überlebende von Krebserkrankungen im Kindesalter („childhood cancer survivors“ [CCS]) haben ein Risiko, später bösartige Neubildungen („subsequent malignancies“ [SMN]) zu entwickeln, die unter anderem auf frühere Therapien zurückzuführen sind. CCS mit zugrunde liegenden Krebsprädispositionssyndromen haben ein zusätzliches genetisches Risiko für die Entwicklung von SMN. Das Tool „McGill Interactive Pediatric OncoGenetic Guidelines“ (MIPOGG) identifiziert Kinder mit Krebs, bei denen eine erhöhte Wahrscheinlichkeit besteht, dass sie ein Krebsprädispositionssyndrom haben. MIPOGG leitet Ärzte durch eine Reihe von Ja- oder Nein-Fragen und führt so zu einer Empfehlung für oder gegen eine genetische Untersuchung. Die Autoren der hier diskutierten Arbeit haben die Fähigkeit von MIPOGG zur Vorhersage der SMN-Entwicklung bei CCS untersucht. …
Literature
1.
Turcotte LM, Liu Q, Yasui Y et al (2019) Chemotherapy and risk of subsequent malignant neoplasms in the childhood cancer survivor study cohort. J Clin Oncol 37(34):3310–3319CrossRef
2.
Teepen JC, van Leeuwen FE, Tissing WJ et al (2017) Long-term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER study cohort: role of chemotherapy. J Clin Oncol 35(20):2288–2298CrossRef
3.
Meadows AT, Strong LC, Li FP et al (1980) Bone sarcoma as a second malignant neoplasm in children: influence of radiation and genetic predisposition for the late effects study group. Cancer 46(12):2603–2606CrossRef
4.
Pole JD, Gu LY, Kirsh V, Greenberg ML, Nathan PC (2015) Subsequent malignant neoplasms in a population-based cohort of pediatric cancer patients: a focus on the first 5 years. Cancer Epidemiol Biomarkers Prev 24(10):1585–1592CrossRef
5.
Pole JD, Darmawikarta D, Gassas A et al (2015) Subsequent malignant neoplasms in pediatric cancer patients treated with and without hematopoietic SCT. Bone Marrow Transplant 50(5):721–726CrossRef
6.
Zong X, Pole JD, Grundy PE, Mahmud SM, Parker L, Hung RJ (2017) Second malignant neoplasms after childhood non-central nervous system embryonal tumours in North America: a population-based study. Eur J Cancer 84:173–183CrossRef
7.
Ripperger T, Bielack SS, Borkhardt A et al (2017) Childhood cancer predisposition syndromes—a concise review and recommendations by the cancer predisposition working group of the society for pediatric oncology and hematology. Am J Med Genet A 173(4):1017–1037CrossRef
8.
9.
Kamran SC, Berrington de Gonzalez A, Ng A, Haas-Kogan D, Viswanathan AN (2016) Therapeutic radiation and the potential risk of second malignancies. Cancer 122(12):1809–1821CrossRef
10.
Rippinger N, Fischer C, Haun MW et al (2020) Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: a multicenter feasibility and acceptance survey. Cancer 126(17):4032–4041CrossRef
11.
Hettmer S, Archer NM, Somers GR et al (2014) Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer 120(7):1068–1075CrossRef
12.
Archer NM, Amorim RP, Naves R et al (2016) An increased risk of second malignant neoplasms after rhabdomyosarcoma: population-based evidence for a cancer predisposition syndrome? Pediatr Blood Cancer 63(2):196–201CrossRef
13.
Wang Z, Wilson CL, Easton J et al (2018) Genetic risk for subsequent neoplasms among long-term survivors of childhood cancer. J Clin Oncol 36(20):2078–2087CrossRef
14.
Zhang J, Walsh MF, Wu G et al (2015) Germline mutations in predisposition genes in pediatric cancer. N Engl J Med 373(24):2336–2346CrossRef
15.
Grobner SN, Worst BC, Weischenfeldt J et al (2018) The landscape of genomic alterations across childhood cancers. Nature 555(7696):321–327CrossRef
16.
Kratz CP, Jongmans MC, Cave H et al (2021) Predisposition to cancer in children and adolescents. Lancet Child Adolesc Health 5(2):142–154CrossRef
17.
Morton LM, Kerns SL, Dolan ME (2018) Role of Germline genetics in identifying survivors at risk for adverse effects of cancer treatment. Am Soc Clin Oncol Educ Book 38:775–786CrossRef
18.
Choi DK, Helenowski I, Hijiya N (2014) Secondary malignancies in pediatric cancer survivors: perspectives and review of the literature. Int J Cancer 135(8):1764–1773CrossRef
19.
Bhatia S (2015) Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors. Cancer 121(5):648–663CrossRef
20.
Goudie C, Witkowski L, Cullinan N et al (2021) Performance of the mcgill interactive pediatric OncoGenetic guidelines for identifying cancer predisposition syndromes. JAMA Oncol 7(12):1806–1814CrossRef
21.
Nguyen TMK, Behnert A, Pietsch T, Vokuhl C, Kratz CP (2021) Proportion of children with cancer that have an indication for genetic counseling and testing based on the cancer type irrespective of other features. Fam Cancer 20(4):273–277CrossRef
22.
Schwermer M, Behnert A, Dorgeloh B, Ripperger T, Kratz CP (2021) Effective identification of cancer predisposition syndromes in children with cancer employing a questionnaire. Fam Cancer 20(4):257–262CrossRef
Metadata
Title
Krebsprädispositions-Screening-Tools zur Vorhersage späterer maligner Erkrankungen bei Überlebenden nach einer Tumorerkrankung im Kindesalter
Author
PD Dr. med. Monika Sparber-Sauer
Publication date
28-05-2022
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 9/2022
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-022-01956-9

Other articles of this Issue 9/2022

Strahlentherapie und Onkologie 9/2022 Go to the issue

Original Article

Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and standard-dose intensity-modulated radiotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study

Original Article

Results of sole postoperative interstitial, high-dose-rate brachytherapy of T1–2 tongue tumours

Literatur kommentiert

Maligne Hodentumoren in der Cisplatin-Ära: Todesursachen und Letalität in einer Kohortenstudie

Original Article

The value of metabolic parameters and textural analysis in predicting prognosis in locally advanced cervical cancer treated with chemoradiotherapy

Original Article

Nomogram for distant metastasis-free survival in patients with locoregionally advanced nasopharyngeal carcinoma

Original Article

Mutagen sensitivity and risk of second cancer in younger adults with head and neck squamous cell cancer: 15-year results